N-[(4-hydroxy-3-methoxyphenyl)methyl]icosa-5,8,11,14-tetraenamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: N-[(4-hydroxy-3-methoxyphenyl)methyl]icosa-5,8,11,14-tetraenamide
• 化学式: C₂₈H₄₁NO₃
• 分子量: 439.6
• InChiKey: QVLMCRFQGHWOPM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.2
• 重原子数：
  32
• 可旋转键数：
  17
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Novel eicosanoid analgesics
  申请人：——

  公开号：US20040122089A1

  公开（公告）日：2004-06-24

  Analogs of andandamide and arvanil have been found to act preferential at CB 1 and AR 1 receptors, and at receptors other than CB 1 and AR 1 . The analogs provide analgesic effects in vivo, and are useful in pain management. In addition, the analogs may be used as anti-proliferative/anti-tumor agents, vasodilators, and in other applications. Several of the anandamide and arvanil analogs are more potent than anandamide and arvanil.

  已发现与anandamide和arvanil类似物作用于CB1和AR1受体时具有优先性，并且还作用于非CB1和AR1受体。这些类似物在体内提供镇痛效果，并在疼痛管理中有用。此外，这些类似物还可以用作抗增殖/抗肿瘤剂、血管扩张剂以及其他应用。几种anandamide和arvanil类似物比anandamide和arvanil更有效。
• USE OF N-ACYLVANILLINAMIDE DERIVATIVES AS AGONISTS OF PERIPHERAL CANNABINOID CB1 RECEPTORS
  申请人：Innovet Italia S.r.l.

  公开号：EP1115392A2

  公开（公告）日：2001-07-18
• USE OF HYPOTHERMIA INDUCING DRUGS
  申请人：Neurokey A/S

  公开号：EP2076255A2

  公开（公告）日：2009-07-08
• MATERIALS AND METHODS FOR INDUCING THERAPEUTIC HYPOTHERMIA IN A MAMMALIAN SUBJECT
  申请人：University of Miami

  公开号：EP3852812A1

  公开（公告）日：2021-07-28
• N-acylvanillinamide derivatives capable of activating peripheral cannabinoid receptors
  申请人：Bisogno Tiziana

  公开号：US20050065216A1

  公开（公告）日：2005-03-24

  The present invention relates to the use of N-acylvanillinamide derivatives capable of activating the peripheral receptor CB1 of cannabinoids. In particular, the present invention relates to the use of compounds of general formula (I) in which the meanings of R, R 1 , R 3 and Y are as defined in the description, for the preparation of a medicinal product which is capable of activating the peripheral receptor CB1 of cannabinoids.